TARS [NASD]
Tarsus Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.69 Insider Own5.10% Shs Outstand20.68M Perf Week18.50%
Market Cap334.55M Forward P/E- EPS next Y-4.85 Insider Trans-24.86% Shs Float20.43M Perf Month-28.72%
Income-13.80M PEG- EPS next Q-0.71 Inst Own49.40% Short Float2.79% Perf Quarter-9.39%
Sales57.00M P/S5.87 EPS this Y48.60% Inst Trans-1.30% Short Ratio4.03 Perf Half Y-52.24%
Book/sh8.06 P/B1.63 EPS next Y-750.90% ROA5.90% Target Price55.29 Perf Year-55.43%
Cash/sh6.74 P/C1.95 EPS next 5Y- ROE6.30% 52W Range10.80 - 39.08 Perf YTD-41.64%
Dividend- P/FCF92.93 EPS past 5Y- ROI-7.30% 52W High-65.81% Beta-
Dividend %- Quick Ratio15.30 Sales past 5Y- Gross Margin96.40% 52W Low23.70% ATR1.26
Employees46 Current Ratio15.30 Sales Q/Q- Oper. Margin22.60% RSI (14)39.45 Volatility11.06% 8.38%
OptionableYes Debt/Eq0.00 EPS Q/Q-28.30% Profit Margin19.80% Rel Volume1.67 Prev Close13.13
ShortableYes LT Debt/Eq0.00 Earnings- Payout0.00% Avg Volume141.65K Price13.36
Recom1.30 SMA20-13.47% SMA50-21.07% SMA200-38.65% Volume87,340 Change1.75%
Dec-21-21Initiated H.C. Wainwright Buy $40
Nov-23-21Initiated Oppenheimer Outperform $55
Nov-10-20Initiated Raymond James Strong Buy $39
Nov-10-20Initiated Ladenburg Thalmann Buy $42
Nov-10-20Initiated Jefferies Buy $35
Nov-10-20Initiated BofA Securities Buy $33
May-14-22 08:19AM  
May-11-22 06:30AM  
May-10-22 06:55PM  
04:05PM  
May-09-22 01:49PM  
May-06-22 09:00AM  
May-05-22 08:30AM  
May-03-22 03:00PM  
06:58AM  
May-02-22 07:01AM  
07:00AM  
Apr-29-22 09:23PM  
Apr-26-22 08:30AM  
Apr-21-22 03:05AM  
Mar-14-22 04:05PM  
Mar-09-22 05:00PM  
Feb-03-22 09:00AM  
Feb-02-22 04:30PM  
07:00AM  
Jan-04-22 09:00AM  
Nov-23-21 04:30PM  
Nov-10-21 04:30PM  
Nov-09-21 04:05PM  
Nov-05-21 12:04PM  
Nov-04-21 11:28AM  
09:45AM  
Nov-02-21 05:00PM  
Oct-19-21 02:38PM  
Oct-11-21 07:43PM  
Aug-13-21 07:07AM  
Aug-12-21 09:00AM  
Aug-07-21 04:20AM  
Aug-04-21 05:30PM  
Jul-24-21 06:00PM  
Jul-20-21 08:37AM  
Jul-07-21 04:05PM  
Jun-26-21 07:34AM  
Jun-22-21 06:00AM  
Jun-21-21 12:52PM  
07:33AM  
06:00AM  
Jun-18-21 04:05PM  
Jun-16-21 04:05PM  
May-24-21 04:05PM  
May-11-21 04:05PM  
May-04-21 04:05PM  
May-03-21 04:08PM  
Apr-27-21 04:05PM  
Apr-20-21 09:09AM  
Mar-31-21 04:05PM  
Mar-30-21 07:14AM  
Mar-29-21 04:05PM  
Jan-19-21 08:30AM  
Jan-18-21 08:43AM  
Jan-07-21 09:24AM  
Jan-05-21 05:00PM  
Dec-23-20 07:00AM  
Dec-21-20 07:00AM  
Nov-19-20 03:24PM  
Nov-13-20 07:35PM  
Oct-20-20 04:05PM  
Oct-16-20 06:05PM  
Oct-15-20 08:35PM  
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase IIb/III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ackermann MichaelDirectorMay 05Buy13.50100,0001,350,000100,000May 09 04:42 PM
Vivo Capital IX, LLC10% OwnerMay 05Sale12.255,37465,8322,469,001May 05 06:55 PM
Vivo Capital IX, LLC10% OwnerMay 04Sale12.6719,738250,0802,474,375May 04 08:01 PM
Vivo Capital IX, LLC10% OwnerMay 03Sale13.25451,4185,981,2882,494,113May 04 08:01 PM
Vivo Capital IX, LLC10% OwnerMay 02Sale15.1941,800634,9422,945,531May 04 08:01 PM
Ackermann MichaelDirectorDec 01Sale24.685,833143,9341,204,016Dec 03 06:56 PM
Azamian Bobak R.President and CEODec 01Sale24.725,833144,1671,204,106Dec 03 06:55 PM
Mottiwala AzizChief Commercial OfficerNov 08Sale28.111,88953,10050,203Nov 10 06:29 PM
Mottiwala AzizChief Commercial OfficerNov 05Sale28.111130952,092Nov 08 05:49 PM
Mottiwala AzizChief Commercial OfficerNov 04Sale28.031002,80352,103Nov 08 05:49 PM
Mottiwala AzizChief Commercial OfficerNov 02Sale26.786,000160,69052,203Nov 04 07:03 PM
Ackermann MichaelDirectorNov 01Sale27.825,833162,2891,209,849Nov 03 07:00 PM
Azamian Bobak R.President and CEONov 01Sale27.825,833162,2841,209,939Nov 03 06:55 PM
Ackermann MichaelDirectorOct 12Sale26.275,633148,0001,215,682Oct 14 04:48 PM
Azamian Bobak R.President and CEOOct 12Sale26.305,531145,4481,215,772Oct 14 04:44 PM
Ackermann MichaelDirectorOct 08Sale25.032005,0061,221,315Oct 12 06:47 PM
Azamian Bobak R.President and CEOOct 08Sale25.023027,5551,221,303Oct 12 06:43 PM
Mottiwala AzizChief Commercial OfficerSep 10Option Exercise7.056,94348,97360,796Sep 14 04:51 PM
Mottiwala AzizChief Commercial OfficerSep 10Sale22.152,59357,43558,203Sep 14 04:51 PM
Azamian Bobak R.President and CEOSep 01Sale25.255,833147,3011,221,605Sep 03 05:51 PM
Ackermann MichaelDirectorSep 01Sale25.245,833147,2371,221,515Sep 03 06:53 PM
Ackermann MichaelDirectorAug 11Sale25.1562115,6191,227,348Aug 12 05:27 PM
Azamian Bobak R.President and CEOAug 11Sale25.071,91748,0611,227,438Aug 12 05:26 PM
Azamian Bobak R.President and CEOAug 10Sale25.001032,5751,229,355Aug 12 05:26 PM
Ackermann MichaelDirectorAug 09Sale25.0070017,5001,227,969Aug 10 04:55 PM
Azamian Bobak R.President and CEOAug 09Sale25.0282720,6881,229,458Aug 10 04:53 PM
Azamian Bobak R.President and CEOAug 06Sale25.001,61640,4001,230,285Aug 10 04:53 PM
Ackermann MichaelDirectorAug 06Sale25.003,12978,2251,228,669Aug 10 04:55 PM
Ackermann MichaelDirectorAug 05Sale25.001,38334,5761,231,798Aug 06 04:16 PM
Azamian Bobak R.President and CEOAug 05Sale25.001,37034,2501,231,901Aug 06 04:14 PM
Vivo Capital IX, LLC10% OwnerJun 25Sale29.607,704228,0382,987,331Jun 25 09:30 PM
Vivo Capital IX, LLC10% OwnerJun 24Sale29.9010,000299,0002,995,035Jun 25 09:30 PM
Vivo Capital IX, LLC10% OwnerJun 23Sale29.8037,9801,131,8043,005,035Jun 25 09:30 PM
Vivo Capital IX, LLC10% OwnerJun 22Sale28.50110,0003,135,0003,043,015Jun 25 08:51 PM
Vivo Capital IX, LLC10% OwnerJun 21Sale29.7091,6202,721,1143,153,015Jun 25 08:51 PM